[A fosfomycin-gentamicin combination in the treatment of experimental endocarditis caused by Klebsiella pneumoniae producing type TEM-3 beta-lactamase].

Abstract

The authors studied the activity of fosfomycin (FOS) and/or gentamicin (GEN) against a Klebsiella pneumoniae strain resistant to all beta-lactams--except cephamycins and imipenem--by production of a plasmid mediated extended broad-spectrum beta-lactamase-TEM-3, to all aminoglycosides--except gentamicin--by production of a plasmid mediated 6' aminoglycoside acetyltransferase IV, to sulfonamides and to tetracyclines. In vitro, the combination FOS (MIC = MBC = 32 mg/l) + GEN (MIC = MBC = 2) appeared indifferent (FIC = 0.75; FBC = 1). In vivo, on experimental endocarditis in rabbits, FOS alone was ineffective, GEN alone was active but only at high dose regimen, FOS - GEN combination was active as compared with controls. Fosfomycin - gentamicin combination may be an alternative in the therapy of severe infections due to multiresistant Enterobacteriacae.

• Authors: F Caron, A Bure, B Pangon, J P Bedos, J M Vallois, C Gaudebout, C Carbon
• Journal: Pathologie-biologie (Pathol Biol (Paris)) Vol. 37 Issue 10 Pg. 1095-7 (Dec 1989) ISSN: 0369-8114 [Print] France
• Vernacular Title: Association fosfomycine-gentamicine dans le traitement d'une endocardite expérimentale à Klebsiella pneumoniae produisant une beta-lactamase de type TEM-3.
• PMID: 2691965 (Publication Type: Journal Article)

Chemical References

• Gentamicins
• Fosfomycin
• beta-Lactamases

Topics

• Animals
• Drug Resistance, Microbial
• Drug Therapy, Combination (pharmacology, therapeutic use)
• Endocarditis, Bacterial (drug therapy)
• Female
• Fosfomycin (pharmacology, therapeutic use)
• Gentamicins (pharmacology, therapeutic use)
• In Vitro Techniques
• Klebsiella Infections (drug therapy)
• Klebsiella pneumoniae (enzymology)
• Rabbits
• beta-Lactamases (biosynthesis)